Home>>10(S)-PAHSA
10(S)-PAHSA Catalog No.GC40318

A stereoisomer of 10-PAHSA

Size Price Stock Qty
500μg
$377.00
In stock
1mg
$715.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. N/A SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES CCCCCCCC[C@H](OC(CCCCCCCCCCCCCCC)=O)CCCCCCCCC(O)=O
Formula C34H66O4 M.Wt 538.9
Solubility DMF: 20 mg/ml,DMSO: 15 mg/ml,Ethanol: 20 mg/ml,Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

10(S)-PAHSA is a stereoisomer of 10-PAHSA , an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs). It is a FAHFA in which palmitic acid is esterified to 10-hydroxy stearic acid. Among the FAHFA family members, PAHSAs are the most abundant in the adipose tissue of glucose tolerant AG4OX mice, which overexpress the Glut4 glucose transporter specifically in adipose tissue. A study using synthesized (R)- and (S)- stereoisomers of 9-PAHSA reported that the 9(R)-PAHSA is the predominant form that accumulates in adipose tissues in vivo. Also, cell lines favor the production of 9(R)-PAHSA and carboxyl ester lipase selectively hydrolyzes 9(S)-PAHSA .The use of this optically-active FAHFA product (the "Product") is covered by U.S. Patent No. 10,240,025 and corresponding foreign counterpart applications.